We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Roche Receives FDA Clearance for Strep A Test


Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Roche Receives FDA Clearance for Strep A Test "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:
 

Roche has announced that the U.S. Food and Drug Administration (FDA) has provided 510(k) clearance for the cobas® Strep A test for the detection of group A streptococcus bacterial (Strep A) DNA in throat swab specimens. The cobas Strep A test runs on the cobas Liat System, a molecular point of care diagnostic system, which will be launched later this year. With a time to result of just 15 minutes, the cobas Strep A test achieves outstanding sensitivity aiding healthcare professionals to make immediate, informed treatment decisions in a variety of testing locations.

Strep A is the cause of strep throat, as well as certain skin infections, scarlet fever, and toxic shock syndrome. About 37% of sore throats among children1 and 5-15% in adults2 are caused by Strep A and infection is most common between the ages of 5 and 153.

“The cobas Strep A test is easy to use and provides accurate results to support a treatment decision in just 15 minutes, much faster than current technologies,” said Roland Diggelmann, COO of Roche Diagnostics. “It also provides a significant improvement over conventional methods such as culture testing, where patients can wait up to 2 days to receive their result, or rapid antigen testing where confirmation with culture is needed due to significantly lower sensitivity.”

The new cobas Strep A test adds to the growing portfolio of assays designed for use with the cobas Liat System, enabling healthcare professionals to perform molecular PCR testing in a variety of settings with speed, accuracy, reliability and minimal training. The analyzer and two initial assays (cobas Influenza A/B and cobas Strep A) are both CE Marked and FDA cleared. Roche expects to begin sales of the system and assays later this year.

Advertisement